GSA Capital Partners LLP Purchases New Position in PROCEPT BioRobotics Corporation $PRCT

Key Points

• GSA Capital Partners acquired 49,269 shares of PROCEPT BioRobotics worth approximately $1.1 million, while institutional investors and hedge funds collectively own 89.46% of the company.
• Analyst sentiment is mixed, with an overall “Hold” rating and an average price target of $28; targets range from $20 to $28 after several firms lowered or maintained their ratings.
• PROCEPT reported quarterly revenue of $94.5 million, up 19.3% year over year, but missed EPS estimates and remains unprofitable. The company also faces securities-fraud allegations related to product demand, inventory issues and an undisclosed handpiece discount program.

GSA Capital Partners LLP purchased a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 49,269 shares of the company's stock, valued at approximately $1,112,000. GSA Capital Partners LLP owned 0.09% of PROCEPT BioRobotics at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Advisory Services Network LLC lifted its holdings in shares of PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company's stock valued at $1,158,000 after acquiring an additional 250 shares during the period. Osaic Holdings Inc. increased its position in shares of PROCEPT BioRobotics by 20.3% during the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company's stock worth $115,000 after purchasing an additional 337 shares in the last quarter. ProShare Advisors LLC increased its position in shares of PROCEPT BioRobotics by 4.7% during the 4th quarter. ProShare Advisors LLC now owns 9,726 shares of the company's stock worth $306,000 after purchasing an additional 438 shares in the last quarter. California State Teachers Retirement System lifted its holdings in PROCEPT BioRobotics by 1.4% during the 2nd quarter. California State Teachers Retirement System now owns 49,446 shares of the company's stock valued at $2,848,000 after purchasing an additional 693 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company's stock valued at $29,000 after purchasing an additional 746 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. TD Cowen decreased their price objective on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, August 5th. Jefferies Financial Group reiterated a "hold" rating and issued a $20.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Evercore set a $23.00 target price on PROCEPT BioRobotics in a report on Wednesday, August 5th. UBS Group lowered PROCEPT BioRobotics from a "buy" rating to a "neutral" rating and set a $20.00 price target on the stock. in a research report on Tuesday, July 28th. Finally, Robert W. Baird set a $20.00 price target on PROCEPT BioRobotics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics presently has an average rating of "Hold" and an average target price of $28.00.

Insider Activity

In other news, CEO Larry L. Wood purchased 23,900 shares of the business's stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the purchase, the chief executive officer directly owned 23,900 shares of the company's stock, valued at $498,315. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 1,000 shares of company stock worth $28,480 over the last quarter. Corporate insiders own 4.00% of the company's stock.

PROCEPT BioRobotics Stock Performance

PRCT stock opened at $21.09 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The company has a 50 day moving average price of $20.92 and a 200 day moving average price of $24.39. PROCEPT BioRobotics Corporation has a fifty-two week low of $16.67 and a fifty-two week high of $42.43. The stock has a market capitalization of $1.21 billion, a PE ratio of -10.87 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The firm had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The firm's quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.35) EPS. Analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Management is scheduled to present and hold investor meetings at the Baird 2026 Global Healthcare Conference in New York on September 15. The event could provide an opportunity to address demand trends and the company’s outlook, although no new financial information was announced. PROCEPT BioRobotics to Attend the Baird 2026 Global Healthcare Conference
• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a lawsuit covering purchases of PROCEPT securities from February 28, 2024, through February 25, 2026. The notices are largely duplicative and do not represent a new court ruling or finding of wrongdoing. Robbins LLP Encourages PRCT Shareholders to Contact the Firm
• Negative Sentiment: The securities-fraud allegations claim PROCEPT made material misstatements or omissions concerning product demand and inventory issues. One complaint-related notice alleges that an undisclosed handpiece discount program inflated recurring-revenue metrics and pulled demand forward; another links the disclosures to an approximately 18% stock decline. If substantiated, the claims could lead to litigation costs, damages, and increased scrutiny of the company’s sales practices and reporting. PROCEPT Securities Fraud Class Action Related to Inventory Issues

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source